Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
International Journal of Obesity (2005)
|
December 19, 2014
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial
R V Seimon, D Espinoza, N Finer, et al.
British Journal of Cancer
|
July 14, 2011
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
C K Lee, H Gurney, C Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
N Lawrence, A Martin, G Toner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2016
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
K Lindemann, G Kristensen, M R Mirza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2017
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
A Bamias, E Gibbs, C Khoon Lee, et al.
British Journal of Cancer
|
March 6, 2015
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
T J Price, M A Bruhn, C K Lee, et al.
Breast (Edinburgh, Scotland)
|
January 8, 2014
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
N McCarthy, F Boyle, N Zdenkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
P S Grimison, M R Stockler, M Chatfield, et al.
BMC Cancer
|
March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
R Mercieca-Bebber, E H Barnes, K Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial
N Zdenkowski, J F Forbes, F M Boyle, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
International Journal of Obesity (2005)
|
December 19, 2014
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial
R V Seimon, D Espinoza, N Finer, et al.
British Journal of Cancer
|
July 14, 2011
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
C K Lee, H Gurney, C Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
N Lawrence, A Martin, G Toner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2016
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
K Lindemann, G Kristensen, M R Mirza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2017
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
A Bamias, E Gibbs, C Khoon Lee, et al.
British Journal of Cancer
|
March 6, 2015
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
T J Price, M A Bruhn, C K Lee, et al.
Breast (Edinburgh, Scotland)
|
January 8, 2014
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
N McCarthy, F Boyle, N Zdenkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
P S Grimison, M R Stockler, M Chatfield, et al.
BMC Cancer
|
March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
R Mercieca-Bebber, E H Barnes, K Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial
N Zdenkowski, J F Forbes, F M Boyle, et al.
Page
of 11